This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Albany Molecular Research Inc (AMRI)

NASDAQ: Health Care

Company Income Statement
Dec 2013 Dec 2012 Dec 2011 Dec 2010
Sales 246.58M 226.69M 207.64M 198.07M
Cost of Sales 155.52M 150.73M 150.32M 135.21M
Gross Operating Profit 91.05M 75.95M 57.33M 62.85M
Selling, General, and Administrative Expenses 45.02M 44.05M 44.76M 55.68M
Research & Development 414.00K 906.00K 7.94M 11.09M
Operating Income before D & A (EBITDA) 45.62M 31.00M 4.64M -3.91M
Depreciation & Amortization 16.40M 17.33M 18.16M 17.46M
Interest Income 11.00K 9.00K 131.00K 452.00K
Other Income - Net 772.00K -130.00K 77.00K -962.00K
Special Income / Charges -1.86M -8.33M -21.34M -47.69M
Total Income Before Interest Expenses (EBIT) 20.96M 582.00K -35.92M -72.67M
Interest Expense 1.26M 463.00K 714.00K 175.00K
Pre-Tax Income 19.70M 119.00K -36.64M -72.84M
Income Taxes 7.02M 3.90M -4.34M -9.97M
Minority Interest 0.00 0.00 0.00 0.00
Net Income From Continuing Operations 12.68M -3.78M -32.30M -62.87M
Net Income From Discontinued Operations 0.00 0.00 0.00 0.00
Net Income From Total Operations 12.68M -3.78M -32.30M -62.87M
Extraordinary Income/Losses 0.00 0.00 0.00 0.00
Income From Cum. Effect of Acct. Change 0.00 0.00 0.00 0.00
Income From Tax Loss Carryforward 0.00 0.00 0.00 0.00
Other Gains / Losses 0.00 0.00 0.00 0.00
Total Net Income 12.68M -3.78M -32.30M -62.87M
Normalized Income
(Net Income From Continuing Operations,
Ex. Special Income / Charge)
21.72M 9.19M -9.68M -12.09M
Preferred Dividends
Net Income Available To Common 12.68M -3.78M -32.30M -62.87M
Basic EPS from Continuing Ops. 0.41 -0.12 -1.08 -2.05
Basic EPS from Discontinued Ops. 0.00 0.00 0.00 0.00
Basic EPS from Total Operations 0.41 -0.12 -1.08 -2.05
Basic EPS from Extraordinary Inc. 0.00 0.00 0.00 0.00
Basic EPS from Cum Effect of Accounting Change 0.00 0.00 0.00 0.00
Basic EPS from Tax Loss Carryf'd. 0.00 0.00 0.00 0.00
Basic EPS from Other Gains (Losses) 0.00 0.00 0.00 0.00
Basic EPS, Total 0.41 -0.12 -1.08 -2.05
Basic Normalized Net Income/Share 0.70 0.30 -0.32 -0.39
EPS fr Continuing Ops. 0.41 -0.12 -1.08 -2.05
EPS fr Discontinued Ops 0.00 0.00 0.00 0.00
EPS fr Total Ops. 0.41 -0.12 -1.08 -2.05
EPS fr Extraord. Inc. 0.00 0.00 0.00 0.00
EPS fr Cum Effect of Accounting Change 0.00 0.00 0.00 0.00
EPS fr Tax Loss Carfd. 0.00 0.00 0.00 0.00
EPS fr Other Gains (L) -0.01 0.00 0.00 0.00
EPS, Total 0.40 -0.12 -1.08 -2.05
Diluted Normalized Net Inc/Shr
(Net Income From Continuing Operations,
Ex. Special Income / Charge)
0.70 0.30 -0.32 -0.39
Dividends Paid per Share 0.00 0.00 0.00 0.00
AMRI News

AMRI Albany Molecular Research Inc

Analysts Ratings for AMRI

Rating Current 1-Mo Ago 2-Mo Ago 3-Mo Ago
Strong Buy 0 0 0 0
Moderate Buy 1 1 1 1
Hold 0 0 0 0
Moderate Sell 0 0 0 0
Strong Sell 1 1 1 1
GET AMRI ANALYST REPORT

Brokerage Partners

AMRI Chatter

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Real Money Pro

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Trifecta Stocks

Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.

Product Features:
  • Model portfolio
  • Trade alerts
  • Recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
Stocks Under $10

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Dividend Stock Advisor

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Breakout Stocks

Bryan Ashenberg, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.

Product Features:
  • Model portfolio
  • Small-cap and mid-cap focus
  • Intraday trade alerts
  • Weekly roundups
Options Profits

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
Top Rated Stocks Top Rated Funds Top Rated ETFs